Sleep Medicine
Volume 7, Issue 4 , Pages 312-318 , June 2006

Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia

  • Thomas Roth

      Affiliations

    • Sleep Disorders and Research Center, Henry Ford Hospital, 2799 West Grand Boulevard, CFP-3, Detroit, MI 48202, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 313 916 5171; fax: +1 313 916 5167.
    • ,
  • David Seiden

      Affiliations

    • Broward Research Group and Sleep Wake Disorders Center of South Florida, Pembroke Pines, FL, USA
    • ,
  • Stephen Sainati

      Affiliations

    • Takeda Global Research and Development Center, Lincolnshire, IL, USA
    • ,
  • Sherry Wang-Weigand

      Affiliations

    • Takeda Global Research and Development Center, Lincolnshire, IL, USA
    • ,
  • Jeffrey Zhang

      Affiliations

    • Takeda Global Research and Development Center, Lincolnshire, IL, USA
    • ,
  • Phyllis Zee

      Affiliations

    • Northwestern University, Chicago, IL, USA

Received 7 October 2005 ,Revised 3 January 2006 ,Accepted 4 January 2006.

References 

  1. Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons: An epidemiologic study of three communities. Sleep. 1995;18:425–432
  2. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985;42:225–232
  3. Ancoli-Israel S, Cooke JR. Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc. 2005;53(Suppl. 7):S264–S271
  4. Dement WC, Miles LE, Carskadon MA. White paper on sleep and aging. J Am Geriatr Soc. 1982;30:25–50
  5. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 national sleep foundation survey. II. Sleep. 1999;22(Suppl. 2):S354–S358
  6. Kryger M, Monjan A, Bliwise D, et al. Sleep, health, and aging. Bridging the gap between science and clinical practice. Geriatrics. 2004;59:24–26[see also pages 29–30]
  7. Wauquier A. Aging and changes in phasic events during sleep. Physiol Behav. 1993;54:803–806
  8. Vitiello MV, Moe KE, Prinz PN. Sleep complaints cosegregate with illness in older adults: clinical research informed by and informing epidemiological studies of sleep. J Psychosom Res. 2002;53:555–559
  9. Engle-Friedman M, Bootzin RR, Hazlewood L, et al. An evaluation of behavioral treatments for insomnia in the older adult. J Clin Psychol. 1992;48:77–90
  10. Kirkwood CK. Management of insomnia. J Am Pharm Assoc. 1999;39:688–696
  11. Ambien [package insert]. New York, NY: Sanofi-Synthelabo, Inc.; 2005.
  12. Sonata [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2003.
  13. Lunesta [package insert]. Marlborough, MA; Sepracor; 2005.
  14. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry. 2005;66(Suppl. 9):31–41
  15. Allain H, Bentue-Ferrer D, Tarral A, et al. Effects on postural oscillation and memory functions of a single dose of zolpidem 5mg, zopiclone 3.75mg and lormetazepam 1mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol. 2003;59:179–188
  16. Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory, and performance effects of hypnotics. Psychopharmacol Berl. 1994;116:130–134
  17. Barbee JG. Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. J Clin Psychiatry. 1993;54(Suppl. 10):86–97
  18. Barker MJ, Greenwood KM, Jackson M, et al. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18:37–48
  19. O'Hanlon J. Residual effects on memory and psychomotor performance of zaleplon and other hypnotic drugs. Primary Care Companion J Clin Psychiatry. 2002;4(Suppl. 1):38–44
  20. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Br Med J. 2005;331:1169
  21. Schneeweiss S, Wang PS. Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information. J Am Geriatr Soc. 2005;53:948–954
  22. Wang PS, Bohn RL, Glynn RJ, et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc. 2001;49:1685–1690
  23. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk?. Arch Intern Med. 2004;164:1567–1572
  24. Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol. 2002;22:576–583
  25. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66:469–476
  26. Jackson WK, Roose SP, Glassman AH. Cardiovascular toxicity of antidepressant medications. Psychopathology. 1987;20:64–74
  27. Byerly MJ, Weber MT, Brooks DL, et al. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging. 2001;18:45–61
  28. Rechlin T. The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart rate variability. J Clin Psychopharmacol. 1994;14:392–395
  29. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000;22:1068–1084
  30. Draganich LF, Zacny J, Klafta J, et al. The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J Gerontol A Biol Sci Med Sci. 2001;56:36–41
  31. Christensen P, Thomsen HY, Pedersen OL, et al. Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients. Psychopharmacology. 2005;87:212–215
  32. Glass JR, Sproule BA, Herrmann N, et al. Acute pharmacological effects of temazepam, diphendydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol. 2003;23:260–268
  33. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93:457–462
  34. Agostini JV, Leo-Summers LS, Inouye SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med. 2001;161:2091–2097
  35. Dubocovich ML, Yun K, Ghoul WM, et al. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. Fed Am Soc Exp Biol J. 1998;12:1211–1220
  36. Roth T, Seiden D, Weigand S, et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia [abstract]. Proceedings of new clinical drug evaluation unit; June 6–9, 2005, Boca Raton, FL. Available from: http://www.nimh.nih.gov/ncdeu/index.cfm. Accessed, 10-20-2005.
  37. Avidan AY, Fries BE, James ML, et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in michigan nursing homes. J Am Geriatr Soc. 2005;53:955–962
  38. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. J Am Med Assoc. 1989;262:3303–3307
  39. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316:363–369
  40. Knegtering H, Eijck M, Huijsman A. Effects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging. 1994;5:192–194
  41. Roth T, Stubbs C, Walsh J. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005;28:303–307
  42. Zammit G, Roth T, Erman M, et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia [abstract]. Sleep. 2005;28(Suppl.):A228
  43. Erman M, Seiden D, Zammit G. Phase II study of the selective ML-1 receptor agonist TAK-375 in subjects with primary chronic insomnia [abstract]. Sleep. 2003;26(Suppl.):A298
  44. Stubbs CM, Karim A. A safety, tolerance, and pharmacokinetic study of five single doses of TAK-375 in healthy adults [abstract]. Sleep. 2003;26(Suppl.):A76
  45. Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: Comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26:261–282
  46. Jaffe JH, Bloor R, Crome I, et al. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction. 2004;99:165–173
  47. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48:301–310
  48. Griffiths R, Suess P, Johnson M. Ramelteon and triazolam in humans: Behavioral effects and abuse potential [abstract]. Sleep. 2005;28(Suppl.):A44
  49. Stevenson S, Cornelisson K, Clarke E, et al. Study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375). Clin Pharmacol Ther. 2004;75:P22

☆ This research was supported by a grant funded by Takeda Pharmaceuticals North America, Inc.

PII: S1389-9457(06)00010-4

doi: 10.1016/j.sleep.2006.01.003

Sleep Medicine
Volume 7, Issue 4 , Pages 312-318 , June 2006

Article Tools

* Image Usage & Resolution